Objective: This study was performed to evaluate the potential influence of cytological differences between pleural effusions on the survival of women with metastatic breast cancer during 30 months of follow-up. Study Design: A hospital-based cohort study was performed. Pleural fluid cytology slides from patients with breast cancer were examined. Cases were grouped according to the pattern of tumor cells (spheroid and isolated), in order to access their prognostic value. Results: The study comprised 87 patients. An isolated cell pattern was associated with higher mortality 30 months after the pleural effusion when compared to a spheroid pattern (p = 0.038). Patients with an isolated cell pattern showed higher risk of dying than patients with spheroid formations. The relative risk after adjustment of intervening variables was 5.336 (95% CI 1.054-27.020). The presence of a triple-negative immunohistochemical pattern significantly increased the risk of mortality before 30 months. Conclusion: Pleural effusion with isolated malignant cells is associated with worse prognosis after 30 months of follow-up.

Keywords:
Breast cancer, Pleural effusion, Survival, Morphology, Cell arrangement, Isolated cells, Spheroid pattern
1.
Koo JS, Jung W, Jeong J: Metastatic breast cancer shows different immunohistochemical phenotype according to metastatic site. Tumori 2010;96:424-432.
2.
Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS: Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167:913-920.
3.
Woodhouse EC, Chuaqui RF, Liotta LA: General mechanisms of metastasis. Cancer 1997;80:1529-1537.
4.
Dewis R, Gribbin J: Breast Cancer: Diagnosis and Treatment. Cardiff, National Collaborating Centre for Cancer (UK), 2009, pp 1-46.
5.
Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
6.
Jung SY, Rosenzweig M, Sereika SM, Linkov F, Brufsky A, Weissfeld JL: Factors associated with mortality after breast cancer metastasis. Cancer Causes Control 2012;23:103-112.
7.
Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K: Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-3277.
8.
Pokieser W, Cassik P, Fischer G, Vesely M, Ulrich W, Peters-Engl C: Malignant pleural and pericardial effusion in invasive breast cancer: impact of the site of the primary tumor. Breast Cancer Res Treat 2004;83:139-142.
9.
Fracchia AA, Knapper WH, Carey JT, Farrow JH: Intrapleural chemotherapy for effusion from metastatic breast carcinoma. Cancer 1970;26:626-629.
10.
Ried M, Hofmann HS: The treatment of pleural carcinosis with malignant pleural effusion. Dtsch Arztebl Int 2013;110:313-318.
11.
Fentiman IS, Millis R, Sexton S, Hayward JL: Pleural effusion in breast cancer: a review of 105 cases. Cancer 1981;47:2087-2092.
12.
Raju RN, Kardinal CG: Pleural effusion in breast carcinoma: analysis of 122 cases. Cancer 1981;48:2524-2527.
13.
Banerjee AK, Willetts I, Robertson JF, Blamey RW: Pleural effusion in breast cancer: a review of the Nottingham experience. Eur J Surg Oncol 1994;20:33-36.
14.
Singer TS, Sulkes A, Biran S: Pleural effusion in breast cancer: influence upon clinical course and survival. Chemioterapia 1986;5:66-69.
15.
van Galen KP, Visser HP, van der Ploeg T, Smorenburg CH: Prognostic factors in patients with breast cancer and malignant pleural effusion. Breast J 2010;16:675-677.
16.
El-Mahdi A, Levene A, Lott S: Observations and management of malignant pleural effusions in breast carcinoma. Johns Hopkins Med J 1973;132:44-49.
17.
Santos GT, Prolla JC, Camillo ND, Zavalhia LS, Ranzi AD, Bica CG: Clinical and pathological factors influencing the survival of breast cancer patients with malignant pleural effusion. J Bras Pneumol 2012;38:487-493.
18.
Konikov N, Bleisch V, Piskie V: Prognostic significance of cytologic diagnoses of effusions. Acta Cytol 1966;10:335-339.
19.
Teixeira LR, Pinto JA, Marchi E: Derrame pleural neoplásico. J Bras Pneumol 2006;32(suppl 4):182-189.
20.
Yamada S, Takeda T, Matsumoto K: Prognostic analysis of malignant pleural and peritoneal effusions. Cancer 1983;51:136-140.
21.
Dietrich M, Goodman SN, Rojas-Corona RR, Emralino AB, Jimenez-Joseph D, Sherman ME: Multivariate analysis of prognostic features in malignant pleural effusions from breast cancer patients. Acta Cytol 1994;38:945-952.
22.
Wiley EL, von Roenn J: Metastatic breast carcinoma in pleural fluid: correlation of morphology with estrogen receptor activity and morphology of the primary carcinoma. Acta Cytol 1990;34:169-174.
23.
Minn AJ, Kang Y, Serganova I, Gupta GP, Giri DD, Doubrovin M, Ponomarev V, Gerald WL, Blasber R, Massagué J: Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumor. J Clin Invest 2005;115:44-55.
24.
Nguyen DX, Bos PD, Massagué J: Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009;9:274-284.
25.
Pistelli M, Pagliacci A, Battelli N, Santinelli A, Biscotti T, Ballastore Z, Berardi R, Cascinu S: Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice. Anticancer Res 2013;33:2737-2742.
26.
Danner DE, Gmelich JT: A comparative study of tumor cells from metastatic carcinoma of the breast in effusions. Acta Cytol 1975;19:509-518.
27.
Russo J, Soule HD, McGrath C, Rich MA: Reexpression of the original tumor pattern by a human breast carcinoma cell line (MCF-7) in sponge culture. J Natl Cancer Inst 1976;56:279-282.
28.
Whitehead RH, Bertoncello I, Webber LM, Pedersen JS: A new human breast carcinoma cell line (PMC42) with stem cell characteristics. I. Morphologic characterization. J Natl Cancer Inst 1983;70:649-661.
29.
Yuhas JM, Tarleton AE, Molzen KB: Multicellular tumor spheroid formation by breast cancer cells isolated from different sites. Cancer Res 1978;38:2486-2491.
30.
Ivascu A, Kubbies M: Diversity of cell-mediated adhesions in breast cancer spheroids. Int J Oncol 2007;31:1403-1413.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.